Woodline Partners’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Woodline Partners’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73,800	Closed	-$907K	–	914
2022 Q4	$907K	Sell	73,800 -51,250	-41%	-$1.22M	0.01%	546
2022 Q3	$4.1M	Buy	+125,050	New	+$3.53M	0.06%	337

Woodline Partners's CINC Position: Q1 2023 in Review

Woodline Partners sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 73,800 shares — an estimated $907K sold.

Woodline Partners first reported a position in CINC in Q3 2022 and held it in 2 quarters. The position peaked at $4.1M in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

Woodline Partners reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Woodline Partners sold 73,800 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $907K.
Woodline Partners first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
Woodline Partners's CinCor Pharma, Inc. Common Stock position peaked at $4.1M in Q3 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.